SystImmune & Biokin Secure First China Approval for Revolutionary Bispecific ADC Iza-bren
China Approves First Bispecific ADC for Nasopharyngeal Cancer: What It Means for Patients and Drug Development China’s National Medical Products Administration (NMPA) has approved Iza-bren (BL-B01D1), a first-in-class bispecific antibody-drug conjugate (ADC), for treating recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of platinum chemotherapy and PD-1/PD-L1 inhibitor therapy. Developed by SystImmune and its parent … Read more